An Adult Spasticity Registry of OnabotulinumtoxinA Treatment
- First Posted Date
- 2013-08-29
- Last Posted Date
- 2019-02-11
- Lead Sponsor
- Allergan
- Target Recruit Count
- 744
- Registration Number
- NCT01930786
- Locations
- 🇺🇸
MS Center of California, Newport Beach, California, United States
🇪🇸Hospital de Conxo (Santiago de Compostela) GALICIA, Santiago De Compestela, Pontevedra, Spain
🇺🇸University of Pittsburgh Medical Center Health System, Pittsburgh, Pennsylvania, United States
A Retrospective Study of Anti-Vascular Endothelial Growth Factor (VEGF) Injections for Retinal Vein Occlusion or Diabetic Macular Edema
Completed
- Conditions
- Retinal Vein OcclusionMacular Edema
- Interventions
- Drug: Anti-VEGF
- First Posted Date
- 2013-08-07
- Last Posted Date
- 2019-04-18
- Lead Sponsor
- Allergan
- Target Recruit Count
- 323
- Registration Number
- NCT01918371
A Safety and Efficacy Study of OnabotulinumtoxinA in Premature Ejaculation
Phase 2
Terminated
- Conditions
- Premature Ejaculation
- Interventions
- Drug: Normal Saline
- First Posted Date
- 2013-08-06
- Last Posted Date
- 2018-10-18
- Lead Sponsor
- Allergan
- Target Recruit Count
- 59
- Registration Number
- NCT01917006
- Locations
- 🇺🇸
Manhattan Medical Research, New York, New York, United States
🇬🇧King's College Hospital, London, United Kingdom
🇬🇧Celerion, Belfast, United Kingdom
A Safety and Efficacy Study of Bimatoprost in Men With Androgenic Alopecia (AGA)
Phase 2
Completed
- Conditions
- AlopeciaAlopecia, AndrogeneticBaldness
- Interventions
- First Posted Date
- 2013-07-22
- Last Posted Date
- 2016-03-22
- Lead Sponsor
- Allergan
- Target Recruit Count
- 244
- Registration Number
- NCT01904721
A Safety and Efficacy Study of OZURDEX® in Macular Edema Associated With Branch Retinal Vein Occlusion
Phase 4
Completed
- Conditions
- Retinal Vein OcclusionMacular Edema
- Interventions
- First Posted Date
- 2013-07-19
- Last Posted Date
- 2019-04-17
- Lead Sponsor
- Allergan
- Target Recruit Count
- 71
- Registration Number
- NCT01903720
A Study to Compare the Safety and Efficacy of a New Eye Drop Formulation With REFRESH PLUS® in Participants Following LASIK Refractive Surgery
Phase 3
Completed
- Conditions
- Bilateral LASIK Surgery
- Interventions
- First Posted Date
- 2013-06-26
- Last Posted Date
- 2019-04-16
- Lead Sponsor
- Allergan
- Target Recruit Count
- 148
- Registration Number
- NCT01886690
A Study to Determine the Prevalence of Inflammatory Dry Eye Disease in Patients Prior to Cataract Removal
Completed
- Conditions
- Dry Eye Syndromes
- Interventions
- Other: No intervention
- First Posted Date
- 2013-06-20
- Last Posted Date
- 2015-12-03
- Lead Sponsor
- Allergan
- Target Recruit Count
- 204
- Registration Number
- NCT01882413
An Efficacy and Safety Study of Bimatoprost 0.01% Alone Compared With Travoprost 0.004% and Timolol 0.5% in Subjects With Glaucoma or Ocular Hypertension
Phase 4
Completed
- Conditions
- GlaucomaOcular Hypertension
- Interventions
- First Posted Date
- 2013-06-19
- Last Posted Date
- 2015-11-30
- Lead Sponsor
- Allergan
- Target Recruit Count
- 93
- Registration Number
- NCT01881126
A Safety, Tolerability and Preliminary Efficacy Study of LiRIS® 400 mg in Women With Interstitial Cystitis (IC) and Hunner's Lesions
Phase 1
Completed
- Conditions
- Chronic Interstitial Cystitis
- Interventions
- Drug: LiRIS® 400 mg
- First Posted Date
- 2013-06-18
- Last Posted Date
- 2015-12-18
- Lead Sponsor
- Allergan
- Target Recruit Count
- 10
- Registration Number
- NCT01879683
- Locations
- 🇺🇸
William Beaumont Hospital, Royal Oak, Michigan, United States
🇺🇸Advance Urology Institute, Daytona Beach, Florida, United States
NATRELLE® 410 X-Style and L-Style Breast Implants Continued Access Study
Not Applicable
Terminated
- Conditions
- Breast ReconstructionBreast Implant RevisionBreast Augmentation
- Interventions
- Device: Anatomically shaped, silicone-filled breast implants with low height/projection or extra-full projection
- First Posted Date
- 2013-06-06
- Last Posted Date
- 2020-06-22
- Lead Sponsor
- Allergan
- Target Recruit Count
- 1951
- Registration Number
- NCT01870869
- Locations
- 🇺🇸
John Decorato, Staten Island, New York, United States
🇺🇸Raymond Isakov, Cleveland, Ohio, United States
🇺🇸Roy Hong, Palo Alto, California, United States
© Copyright 2025. All Rights Reserved by MedPath